Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials

Autor: Bar-Or, Amit, Thanei, Gian-Andrea, Harp, Christopher, Bernasconi, Corrado, Bonati, Ulrike, Cross, Anne H., Fischer, Saloumeh, Gaetano, Laura, Hauser, Stephen L., Hendricks, Robert, Kappos, Ludwig, Kuhle, Jens, Leppert, David, Model, Fabian, Sauter, Annette, Koendgen, Harold, Jia, Xiaoming, Herman, Ann E.
Zdroj: In eBioMedicine July 2023 93
Databáze: ScienceDirect